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Salivary Biomarkers to Assess 
Breast Cancer Diagnosis and 
Progression: Are We There Yet?
Charles F. Streckfus
Abstract
Technological developments are propelling medical diagnostics forward at 
unprecedented rates. Advancements in genomic, proteomics and cellomics are lead-
ing the way for diagnostic tests that will be capable of rapid multi-analyte detection 
in both laboratory and non-laboratory settings. Currently, proof-of-principle has 
been demonstrated for salivary biomarkers, whose up and down regulation has 
been shown to correlate strongly with breast cancer among women. Consequently, 
the rationale for this chapter is to review the medical literature and present the 
current research focused on the use of saliva as a diagnostic medium for the study of 
early breast cancer progression.
Keywords: breast cancer progression, saliva, cancer proteomics, breast cancer, 
omics, cancer detection, Her2/neu, mass spectrometry, cancer molecular pathways
1. Introduction
Reducing the overall morbidity and mortality rates for carcinoma of the breast 
is the overall goal of the Department of Health and Human Services [1]. As stated 
in Healthy People 2020, breast cancer is the second leading cause of death in women 
in the United States, with over 45,000 women dying from the disease each year. 
Additionally, in the United States, in 2019, it is estimated that 268,600 women and 
2670 men will be diagnosed with invasive breast cancer. Additionally, another 
62,930 women will be diagnosed with in situ breast cancer [2–7].
Taken together, the chances of a woman being diagnosed with breast cancer dur-
ing her lifetime have increased. In 1975, the rate was 1 in 11; whereupon today the 
rate is roughly 1 in 8 [2]. Overall, the number of women being diagnosed continues 
to increase. This is due in part to the increase in the number of women in age groups 
at risk of breast cancer. Currently, the median age at which breast cancer is diag-
nosed is 62 [4–7].
There is also an increase in breast cancer screening which has resulted in a 
dramatic increase in the incidence of ductal carcinoma in situ (DCIS). DCIS is an 
early stage, pre-invasive form of breast cancer with a cause-specific survival rate 
of approximately 100%. The current problem, however, is that it is not possible to 
distinguish DCIS that will develop into invasive cancer. Consequently, the over-
diagnosis and overtreatment of DCIS remains a persistent problem [8, 9].
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While breast cancer screening with mammography has been shown in 
randomized controlled trials to reduce breast cancer-specific mortality, there 
remains ongoing controversy regarding the value of mammography and its 
utilization.
Additionally, studies using mathematical modeling suggest that more frequent 
mammographic screening would further increase patient survival. Analysis of 
these data suggests a 96% survival rate if patients could receive a mammogram 
every 3 months. However, due to the costs coupled with the invasiveness of the 
procedure, this increase in the frequency of mammography is currently not 
feasible [10].
While advances in imaging have increased breast cancer detectability there are 
still overarching challenges that need to be addressed. The FY19 BCRP  funding 
announcement succinctly outlines these challenges [11]: (1) prevent breast  cancer, 
(2) identify determinants of breast cancer initiation, risk, or susceptibility, 
(3) distinguish deadly from non-deadly breast cancers, (4) address the problems of 
over-diagnosis and overtreatment, (5) identify what drives breast cancer growth; 
and determine how to stop it, (6) identify why some breast cancers become 
metastatic, (7) determine why/how breast cancer cells lie dormant for years and 
then re-emerge, (8) determine how to prevent lethal recurrence, (9) revolutionize 
treatment regimens by replacing them with ones that are more effective, less toxic, 
and impact survival, and (10) eliminate the mortality associated with metastatic 
cancer [11, 12].
The author would like to add two more items: (1) ascertain methods to 
 determine the efficacy of treatment and (2) ascertain methods to determine that 
the treated patient is not only in clinical remission, but in molecular remission as well 
[13, 14]. The latter action items would assure successful treatment.
Taken together, there remains a necessity to identify novel approaches that 
improve breast cancer screening and early detection. This, in turn, reduces the 
problems of over-diagnosis and over-treatment and can detect cancers at a point 
where interventions maybe more effective [1–14].
2. Significant single analyte salivary biomarker studies
There is a paucity of studies in the medical literature concerning the use of saliva 
for the detection of breast cancer. These reports deal primarily with the identifica-
tion and quantification of cancer-related proteins, in saliva that were previously 
discovered to be present in serum or cancer tissue supernatants of diagnosed cancer 
patients. The importance of these studies establishes the basic groundwork and 
feasibility of salivary cancer diagnostics and ascertains the basis for continued 
biomarker research [15].
2.1 Kallikrein
A study that serves to establish the basis for salivary cancer biomarker research 
methodology comes from a report of kallikrein being used as a diagnostic marker. 
The investigation reports the use of saliva to detect variations in the concentrations 
of kallikrein, a regulatory protease, among healthy individuals and patients with 
malignant breast and gastro-intestinal tumors. The outcome of their investigation 
revealed elevated concentrations of salivary kallikrein among individuals diagnosed 
with malignant tumors in comparison with those individuals diagnosed with benign 
tumors and those from a healthy cohort. Kallikrein was measured by chromogenic 
tripeptide assay [16].
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2.2 Epidermal growth factor
Epidermal growth factor (EGF) is a regulatory growth factor protein respon-
sible for tissue growth and repair [17]. Since EGF overexpression is implicated in 
tumorigenesis, it may therefore be useful as a tumor marker. Based on this thinking, 
an additional study [17] demonstrated that EGF concentrations were higher in 
the saliva of women with primary or recurrent breast cancer in comparison with 
women lacking a malignancy [17]. The highest concentrations of EGF were found 
in the local recurrence subgroup, suggesting a potential use for this marker in the 
post-operative follow-up of diagnosed cancer patients [18].
2.3 The Her2/neu studies
Salivary Her2/neu (e-erbB-2) is probably the most thoroughly investigated 
biomarker [19–21] that is still under current investigation [22–24]. The original 
investigators [19–21] selected the salivary protein as the biomarker of choice, 
because this protein was previously shown to be immunohistologically present on the 
membrane of the ductal epithelium of salivary gland tissues [25, 26]. Additionally, 
Her2/neu was found in serum [27] and, therefore, provided the investigators with 
a basis for analytical humoral comparison [28]. Collectively, these points provided 
the basis for the selection of Her2/neu as a salivary biomarker. CA 15-3 was the gold 
standard for comparison in both the saliva and serum specimens [19–21].
The results of these studies demonstrated elevated concentrations of the Her2/neu 
and CA 15-3 proteins in the saliva and serum of all three groups of women. The sali-
vary and serological levels of Her2/neu among the cancer patients were significantly 
higher (p < 0.001) than the salivary and serum levels of healthy controls and benign 
tumor patients. Additionally, the Her2/neu protein was found to be equal to or to 
surpass the ability of CA 15-3 to detect cancer patients. The sensitivity and specificity 
were 87 and 65%, respectively, with a cut-point of 100 Units/ml. These results were 
comparable with the serum levels of Her2/neu [19–21]. Tumor staging and receptor 
status were also assessed. Her2/neu increased with staging, but not with Her2/neu 
status. The finding was later supported by other researchers [23, 29].
Concurrent with the aforementioned investigation, studies to determine the 
relationship between Her2/neu protein concentrations and various demographic 
and clinical variables we conducted. These variables potentially could confound the 
results of any salivary biomarker research. Consequently, the effects of race, age, 
weight, BMI, tobacco usage, alcohol consumption systemic illnesses (e.g., diabetes, 
hypertension, etc.), the use of prescription medications, hormonal status and estro-
gen usage [30], salivary flow rates, marker contributions from epithelia present in 
saliva, and the presence of periodontal disease on salivary Her2/neu concentrations 
were assessed. Edentulous patients were also assessed to control for the effects of 
periodontal disease. These studies show that these potentially confounding vari-
ables exact no effect on salivary Her2/neu concentrations [19–21].
Two other questions that needed to be answered are as follows: could the pun-
gent chemotherapeutics used in cancer treatment adversely affect Her2/neu salivary 
concentrations and secondly could tumor removal and post-chemotherapy events 
modulate, in this case lower, salivary Her2/neu concentrations. In response, a study 
was conducted to answer the aforementioned questions and to establish the utility 
of the salivary Her2/neu in monitoring patients diagnosed with carcinoma of the 
breast before and after treatment.
Twenty-five patients with various stages of carcinoma of the breast were followed 
through the course of treatment. ELISA assays for Her2/neu and CA 15-3 were per-
formed on their serum and stimulated whole-saliva specimens. These baseline samples 
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were collected from all patients prior to the administration of any adjunct therapy or 
surgery and were sequentially sampled during therapy and after their treatment. As 
noted in Figure 1, the outcome of the study demonstrated the modulation of  
Her2/neu concentrations in response to chemotherapeutic treatment. Additionally, 
it may be useful to detect post-treatment recurrence. Indeed, salivary Her2/neu may 
have the potential to track treatment success and guide therapy. The salivary Her2/neu 
determinations also mirrored those for serum Her2/neu and CA 15-3 [31].
Finally, a clinical experiment was conducted to ascertain the reliability and 
repeatability of detecting Her2/neu in both 9 healthy men and 10 healthy women 
over a 5-day time-period [32]. The individuals were saliva sampled at 9 am., 4 pm. 
and 9 pm. over the 5-day period. The samples were stored at −80°C and later 
assayed by ELISA for the Her2/neu protein. The results exhibited no demonstrable 
salivary Her2/neu differences regarding gender, day or time of collection. Inter and 
intra correlation coefficients did decrease in the 4 pm. and 9 pm. collections sug-
gesting that morning to afternoon collections may be optimal for collecting salivary 
Her2/neu specimens [32].
2.3.1 Other supporting experiments
Other technologies were employed to support the aforementioned clinical findings 
[32]. Using Her2/neu antibodies, the authors executed several Western blot experi-
ments. The first of these experiments compared saliva and serum concentrations of 
Her2/neu in specimens from among seven healthy subjects. The blot demonstrated 
protein presence at a range of 170–185 kDa, with denser bands being revealed in the 
salivary samples. A second Western blot to ascertain which salivary gland(s) were 
producing the salivary Her2/neu. Saliva collected from the parotid and submandibular 
glands, and total whole saliva, were sampled from two healthy individuals. The results 
Figure 1. 
An example of post-operative monitoring. The upper graph represents salivary and serum c-erbB-2 
concentrations across time of treatment. The lower graph represents salivary and serum CA 15-3 concentrations 
across time of treatment. As illustrated, the c-erbB-2 concentrations are in concordance with the commonly used 
CA 15-3 cancer biomarker [31].
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suggest that all the major salivary glands were contributors of Her2/neu salivary 
secretions regardless if the glands were serous (parotid) or mixed (submandibular) 
saliva producers. A third experiment compared Her2/neu salivary secretions between 
three individuals diagnosed with carcinoma of the breast and two healthy controls. 
The Western blot demonstrated denser 170–185-kDa bands among the cancer subjects 
as compared with healthy controls. The conclusions derived from these experiments 
suggest that Her2/neu is increased in saliva secondary to carcinoma of the breast [33].
An animal study was also conducted determine if Her2/neu can be detected from 
a remote areas of the body [34]. Male rat saliva does not contain salivary Her2/neu. 
Consequently, two male Sprague-Dawley rats, each weighing between 300 and 500 g, 
were used. One experimental animal received 200 μl, and the other, 500 μl, of encap-
sulated Her2/neu protein. The capsulated Her2/neu proteins were placed in the perito-
neum of each rat. Prior to capsule placement, baseline serum and saliva samples were 
taken. Samples were also taken 20, 68, 140, 188, 308 and 356 hours post-placement. 
Saliva flow was induced by administration of ophthalmic pilocarpine prior to sampling. 
All samples were kept at −20°C. Antibody detection was performed using a modified 
double capture ELISA system. The animal receiving the higher antibody concentration 
showed a markedly greater salivary level of the antibody than the other (peak 24.158 vs. 
18.313 HNU/ml at 308 and 188 hours post-implantation, respectively). Baseline values 
were below detection for both animals. These results appear to indicate that Her2/neu 
may be detected from remote areas of the body [34].
A different type of platform, surface-enhanced laser desorption/ionization mass 
spectrometry (SELDI), was employed to confirm the presence and alteration of 
Her2/neu in saliva [35]. The results of the preliminary SELDI assays were encourag-
ing. The weak cation exchange (WCX @ pH 3.5) biochip demonstrated the most 
potential for profiling salivary proteins. Interestingly, a protein cluster in the range 
of 170 kDa (Figure 2) was more prevalent in cancer patient saliva samples than in 
Figure 2. 
The 113 and 117 kDa spectral peaks in saliva. Additionally, bar graphs to the right show mean values for the 113 
and 117 kDa spectral peaks [35].
Saliva and Salivary Diagnostics
6
samples from normal subjects [36]. Also of note, one of the donors in the normal 
group (XD) is known by ELISA to have quite high Her2/neu levels and stands out 
from the other two normal donors in this analysis. These similar results were also 
demonstrated by serum and the extract from the SKBR-3 breast cancer cell lines 
with SELDI analyses.
In addition, an increase of the proteins in this range from cancer patient saliva, 
especially in the range of approximately 113 kDa, can be seen in Figure 2. One 
possible cancer-related biomarker is the extracellular domain (ECD) of Her2/neu 
receptor, which is approximately 110 kDa (deglycosylated), based on two-dimen-
sional and Western blot gel analyses.
3. Proteomics studies for salivary biomarkers and their findings
Mass spectrometry and liquid chromatography have enabled the researchers to 
analyze complex peptide mixtures with the ability to detect proteins differing in 
abundance by over eight orders of magnitude. Isotopic labeling coupled with liquid 
chromatography tandem mass spectrometry (IL-LC-MS/MS) is often used to char-
acterize the salivary proteome. The approach readily identifies changes in the level 
of expression, thus permitting the analysis of putative regulatory pathways provid-
ing information regarding the pathological disturbances in addition to potential 
biomarkers of disease.
A PubMed.gov database search yielded a paucity of manuscripts (15) using 
LC/MS/MS mass spectrometry. The majority of the manuscripts were composed 
by the author of this chapter [37–40]. In these manuscripts, the researchers used 
an Applied Biosystems QStar® XL LC/MS/MS mass spectrometer equipped with 
an LC Packings high performance liquid chromatography (HPLC) for capillary 
chromatography. The HPLC was coupled to the mass spectrometer by a nanospray 
ESI head for maximal sensitivity. The advantage of tandem mass spectrometry 
combined with LC is enhanced sensitivity and the peptide separations afforded by 
chromatography. Thus even in complex protein mixtures MS/MS data can be used 
to sequence and identify peptides either by peptide similarity or sequence analysis 
with a high degree of confidence [41–44].
The researchers employed iTRAQ reagents [37–39] that are amino reactive 
compounds. The real advantage of using iTRAQ is that the tags remain intact 
through TOF MS analysis. This in turn enables the tags to be revealed during 
collision-induced dissociation by MS/MS analysis. Thus in the MS/MS spectrum for 
each peptide, there is a pattern indicating the quantity of that peptide from each of 
the different protein pools. Essentially all of the peptides in a mixture are labeled by 
the reaction; numerous proteins are identified and can be compared for their rela-
tive concentrations in each mixture. Thus, even in complex mixtures there is a high 
degree of confidence in the identification because of the large number of peptides 
that can be used for protein identification.
Pooled samples were used in these studies with full knowledge of the advantages 
and shortcomings for the technique [45]. Considering that, the exploratory findings 
would have to be validated using other laboratory methodologies, the researchers 
decided to use the pooled sample technique. Sample size for the pooled specimens 
was also calculated [45]. The sample size for each pool was 10 subjects. Additionally, 
the authors used a positive control (benign tumors), which is not found in many of the 
breast cancer biomarker experiments using saliva as the diagnostic media. To enhance 
the study, the same samples were assayed by a blinded outside laboratory [37].
Using the LC-MS/MS platform, the researchers used a three-prong approach to 
obtain salivary protein profiles of cancer patients. The first was to determine if the 
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technology could detect the smallest ductal carcinoma lesions (Stage 0, Stage I) and 
compare their profiles to those of a positive control (fibroadenomas) and healthy 
individuals [37]. The second parameter was to determine protein profile differ-
ences between lymph node positive and lymph node negative cancer patients [38]. 
Third experiment was to ascertain differences between Her2/neu receptor positive 
and Her2/neu receptor negative individuals [39]. Taken together, these three major 
parameters influence tumor progression.
The initial study compared the protein profiles of four cohorts: healthy, benign 
tumor, Stage 0 and Stage I [37]. The PathwayStudio® software, a bioinformatics 
software package was used to determine the fold increase/decrease and p-values. 
p-Values equal to or less than 0.001 were used to select the best biomarker candi-
dates. The number of proteins for each group is shown in Table 1.
The panel (Table 1) has putative markers that are both up and/or down regu-
lated and have varying cellular functions. These proteins are validated in cell studies 
and found altered in the presence of carcinoma of the breast.
The aim of the second study was to compare the salivary protein profiles of pooled 
saliva specimens from individuals diagnosed with ductal carcinoma of the breast 
Comparison Upregulated Downregulated Total markers
Healthy vs. benign 19 10 29
Healthy vs. Stage 0 15 15 30
Healthy vs. Stage I 9 17 26
Benign vs. cancers 9 6 15
Table 1. 
The up- and downregulated proteins for each cohort.
Figure 3. 
The differential expression of salivary proteins common and different to both Stage IIa and Stage IIb [38].
Saliva and Salivary Diagnostics
8
with and without lymph node involvement [38]. Three pooled (n = 10 subjects/
pooled specimen) stimulated whole saliva specimens from women were analyzed. 
One pooled specimen was from healthy women, another pooled specimen was from 
women diagnosed with Stage IIa (T2N0M0) invasive ductal carcinoma (IDC) without 
lymph node involvement and one pooled specimen was from women diagnosed 
with Stage IIb (T2N1M0) with lymph node involvement. Experimentally, saliva from 
each of the pooled samples was trypsinized and the peptide digests labeled with the 
appropriate iTRAQ reagent. The results are shown in Figure 3. The analyses yielded 
approximately 174 differentially expressed proteins in the saliva specimens. Fifty-five 
proteins were common to both cancer stages while there were there were 20 proteins 
unique to Stage IIa and 28 proteins that were unique to Stage IIb. The proteins are 
listed in Figure 3. The study suggests that salivary proteomic profiles may be useful in 
determining lymph node involvement among cancer patients [38].
The third aspect was to compare the salivary profiles from subjects diagnosed 
with breast cancer that were either Her2/neu receptor positive or negative. As previ-
ously mentioned, two pooled saliva specimens underwent proteomic analysis. One 
pooled specimen was from women diagnosed with Stage IIa, Her2/neu receptor posi-
tive breast cancer patients (n = 10) and the other was from women diagnosed with 
Stage IIb, Her2/neu receptor negative (n = 10). The pooled samples were trypsinized 
and the peptides labeled with iTRAQ reagent. Specimens were analyzed using a 
LC-MS/MS mass spectrometer. The results yielded approximately 71 differentially 
expressed proteins in the saliva specimens. There were 34 up-regulated proteins and 
37 down regulated proteins. Figure 4 provides a visualization of the saliva protein 
differences between positive and negative Her2/neu receptor status [39].
Validation of the makers resulting from these studies was performed in a num-
ber of studies [46–49]. The results of all these studies plus numerous others were 
finally comprised into a manuscript, which presents a catalogue of salivary proteins 
that have been altered in the presence of ductal carcinoma of the breast. These 
findings are supported by other proteomic analysis of breast cancer cell lines, breast 
cancer tissues, tissue microenvironment and serum [40]. Additionally, nearly 29% 
of the panel of proteins has been technically validated by either Western blot or by 
ELISA. A breakdown of these proteins has also been analyzed according staging and 
Her2/neu receptor status. All of the proteins were sorted according to their function. 
A pathway analysis was also employed. The investigators have also found that the 
protein concentrations can be modulated while undergoing cancer treatment and 
respond differently according pathological cell type [40].
Figure 4. 
The protein profiles for HER2/neu receptor positive and HER2/neu receptor negative samples. As shown in the 
far right red and green dyed gel comparisons, there are numerous differences between the two profiles [39].
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One major result of these and other studies is the standardization of saliva 
collection and preparation for storage [50]. Additionally, standards for proteomic 
analysis have been established [51].
4. Salivary transcriptome: mRNA and miRNA
In a number of studies conducted by Wong et al., they discovered the presence 
and utility of mRNA in saliva for the detection of breast cancer [52–55]. These find-
ings not only provided researchers with a new source of biomarkers, but also a new 
method for cross-validating proteomic findings [55]. Taken together, these studies 
helped explain preexisting studies and further served to illustrate the complexity of 
salivary composition [52–55].
Concurrent with these studies, were investigations assessing salivary miRNA as 
potential biomarkers for breast cancer detection [56, 57]. These studies also dem-
onstrated how gene microarray and quantitative real-time PCR technology, could 
detect micro-RNA candidates [56, 57]. It has been demonstrated that, secondary to 
breast cancer, salivary micro-RNA profiles are altered [56, 57].
5. Salivary exosomes and microvesicles
One of the major questions regarding salivary biomarker research is how large pro-
teins, mRNA and miRNA enter the saliva proper. Many proteins are too large to pass 
through the intercellular spaces of the acinar cells. So how do they enter whole saliva? 
Additionally, RNAs are intracellular proteins making the problem even more complex.
In 2012, Lau and Wong demonstrated how these particulates might enter the 
saliva via exosome—like microvesicles [58]. The investigators employed an in vitro 
breast cancer model that demonstrated that breast cancer derived exosome—like 
Figure 5. 
An electron micrograph of extracellular vesicles (courtesy of Maija Puhka, Ph.D. of the EV CORE and Institute 
for Molecular Medicine Finland FIMM, University of Helsinki, Finland).
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microvesicles interact with salivary gland cells and produce an altered salivary 
profile. Within these exosome—like microvesicles they found proteins and 
mRNA. They also found that the exosome—like microvesicles communicated and 
activated the transcriptional activity of the salivary glands. The result of this activ-
ity altered the composition of salivary gland exosome—like microvesicles and the 
ensuing salivary secretion [58].
Subsequent research has yielded numerous vesicular structures, which can 
bind to a suitable receptor on a target cell [59–61]. These bodies include exosomes, 
ectosomes, apoptotic bodies and extracellular vesicles (Figure 5). Once thought 
to be repositories for cellular waste, these vesicular bodies provide intricate func-
tions in intercellular communication and compound exchange. Current research is 
demonstrating that these vesicular bodies mediate disease progression. Subsequent 
research has shown this finding to be of great utility in under-standing altered 
salivary composition secondary to various disease states [59–61].
It is also worth noting that extracellular vesicles may also explain the findings 
reported in Section 2.2 of this chapter as Andre et al. extracted Her2/neu from 
exosomal pellets [62]. This may be the underlying mechanism by which biomarker 
proteins enter saliva.
6. Metabolites
In a study conducted by Sugimoto et al., the investigators assessed the diagnos-
tic utility metabolites in saliva [63]. They conducted a comprehensive metabolite 
analysis of saliva samples obtained from 215 individuals. Sixty-nine subjects were 
diagnosed with oral cancer, 18 with pancreatic cancer and 30 with carcinoma of 
the breast. These cohorts were compared to 11 periodontal disease patients and 
87 healthy controls. They used capillary electrophoresis time-of-flight mass spec-
trometry (CE-TOF-MS). Fifty-seven principal metabolites were identified that 
accurately predicted the probability of being affected by each individual disease. 
Additionally they were found that between the known patient characteristics and 
the quantified metabolites, the profiles manifested relatively higher concentra-
tions in most of the metabolites in all three cancers as compared to those in people 
with periodontal disease and control subjects. Several metabolites in breast cancer 
patients yielded a statistically significant difference between breast cancer and 
healthy controls, including taurine and lysine. However, there were no differences 
in metabolites between breast cancer and other two cancers. These metabolites are 
promising biomarkers for cancer screening [63, 64].
7. Conclusions
Based on the volume of evidence provided in this review, the author believes that 
that saliva may have diagnostic potential and the potential to be used to study breast 
cancer progression. As described throughout this text, different analytes using 
various biochemical platforms have all indicated that the constituents in saliva 
are altered secondary to breast cancer. The logistic utility of this media has been 
described in numerous manuscripts; however, to date there are no FDA approved 
salivary diagnostic devices for the detection of breast on the commercial market 
despite the fact that many of these findings have been patented.
Considering the logistical advantages of salivary diagnostic testing and the 
deadliness of the disease we are trying to detect, it would be extremely useful 
to continue to explore the possibility of using saliva as a medium for treatment 
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efficacy and tumor recurrence. Post-treatment monitoring for breast cancer 
recurrence is extremely important. The patient may be in clinical remission but not 
necessarily in molecular remission [40, 65]. This could be accomplished using a 
microarray containing salivary marker of the varying cancer pathways associated 
with carcinoma of the breast [40]. Post-treatment serial sampling would indicate 
the efficacy and indicate protein changes, which could lead to tumor recurrence.
Besides commercialization, Karachi et al. (1985) presented a lingering prob-
lem to the salivary research community [65]. While at N.I.H., he conducted 
an experiment whereby he removed the submandibular gland of virgin mice 
14–22 weeks old. This resulted in a reduced the tumor incidence to 12.8% 
(n = 39) at the age of 52 weeks and also increased the latency period of mammary 
tumor development as much as 14 weeks when compared to that of normal mice. 
Long-term treatment of sialoadenectomized virgin mice with EGF increased 
the tumor incidence to 33.3%. Moreover, sialoadenectomy of mammary tumor-
bearing animals caused a rapid and sustained cessation of tumor growth, but 
EGF administration quickly restored the rate of tumor growth to a normal level. 
These results indicate that submandibular gland EGF plays a crucial role in 
mouse mammary tumorigenesis [65].
The aforementioned study suggests an influence of salivary EGF on tumorigen-
esis. Additionally, it is known from other salivary studies that EGF is elevated in 
human saliva secondary to breast cancer [17, 18]. Could the same effect mentioned 
by Karachi be taking place in humans? [65].
In addition, another study reported an increase in salivary protein rich peptides 
levels among breast cancer patients [40, 48]. Using a proline rich peptide segment 
(p1978) from the parent SMR3B protein peptide in saliva, the researchers found 
that this peptide inhibited the growth of HCC38 triple-negative cancer cells [48]. 
Perhaps the elevation of in of this peptide is in response to tumor proliferation. It 
is known that proline-rich-peptides have a high affinity to the Grb2/SH3 domain, 
which in turn inhibits Ras activation by blocking Sos binding to Grb2 receptor. 
Taken together both studies suggest feedback systems as illustrated in Figure 6.
Figure 6. 
Feedback systems going from saliva to the tumor [65], from saliva in response to the tumor [48] and from the 
tumor to healthy breast tissues [66] and saliva [20, 21].
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In addition, Kuerer [28] found that healthy contralateral breast aspirates exhib-
ited elevated Her2/neu concentrations secondary to carcinoma in the opposite 
breast [66]. This supported the findings of Streckfus, where salivary Her2/neu 
concentrations secondary to carcinoma of the breast [21]. These findings suggest 
inter-exocrine gland communication perhaps by microvesicles and/or exosomes.
Taken together, the author presents sufficient evidence of the interrelationship 
of exocrine tissues and the possibility of using saliva not only as a diagnostic media, 
also to study or assess breast cancer progression.
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